logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Discover
NBIX
Neurocrine Biosciences, Inc.
167.77
2 x 153.83
2 x 180.97
bid
ask
-
0.76
0.45%
2 @ 05:57 AM
171.86 +4.09 (2.44%)
Ytd18.29%
1y29.65%
165.91
day range
169.56
122.14
52 week range
171.50
Open168.75Prev Close168.53Low165.91High169.56Mkt Cap16.87B
Vol917.25KAvg Vol1.23MEPS6.49P/E25.85Forward P/E13.32
Beta0.40Short Ratio4.97Inst. Own103.80%DividendN/ADiv YieldN/A
Ex Div Date12-29Earning07-2950-d Avg153.26200-d Avg142.251yr Est195.99

NBIX News

benzinga.com
Neurocrine Biosciences Initiates Phase 2 Clinical Study To Assess Crinecerfont In Children Aged 3 Mo

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the initiation of its Phase 2 clinical st

Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia
prnewswire.com
Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years O

SAN DIEGO, July 1, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced

Neurocrine Biosciences (NBIX) Is Up 6.46% in One Week: What You Should Know
zacks.com
Neurocrine Biosciences (NBIX) Is Up 6.46% in One Week: What You Should Know

Does Neurocrine Biosciences (NBIX) have what it takes to be a top stock pick for momentum investors?

5 Relative Price Strength Stocks to Buy for the Second Half
zacks.com
5 Relative Price Strength Stocks to Buy for the Second Half

NBIX, MYRG, XYZ, DK and DY show strong relative price strength, upbeat estimate revisions and solid

benzinga.com
Neurocrine Biosciences' Soleno Therapeutics Announces Late-Breaking Data At ENDO 2026 Showing Two Ye

Participants who resumed VYKAT XR following a 16-week randomized withdrawal period demonstrated impr
benzinga.com
Neurocrine Biosciences Presents New Two-Year Data From Phase 3 CAHtalyst Pediatric Trial Of CRENESSI

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new two-year data from the Phase 3 CAHta

Tom Lee's Small-Cap Granny Shots ETF Reloads: First Solar, Zoom Among 10 New Buys
benzinga.com
Tom Lee's Small-Cap Granny Shots ETF Reloads: First Solar, Zoom Among 10 New Buys

Tom Lee's GRNJ added First Solar, Zoom and eight other stocks in its latest rebalance as assets

benzinga.com
Neurocrine Biosciences Reports Rapid Tardive Dyskinesia Improvement With INGREZZA In Patients With I

Nearly all individuals with intellectual and developmental disabilities experienced improvement in t
benzinga.com
Neurocrine Biosciences To Present Multiple New Analyses Of Key Clinical And Patient-Reported Outcome

Analyses span adult and pediatric populations with classic congenital adrenal hyperplasia (CAH) and

benzinga.com
Goldman Sachs Reinstates Buy on Neurocrine Biosciences, Announces $213 Price Target

Goldman Sachs analyst Corinne Johnson reinstates Neurocrine Biosciences (NASDAQ:NBIX) with a Buy